Bausch + Lomb (BLCO) Corporation announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite Vision Enhancement System. “Retinal surgeons who are familiar with our Bi-Blade technology understand the benefits of its dual-port design, 100% open duty cycle and cutting speed of 15,000 cuts per minute,” said Wayne Caulder, vice president and general manager, North America Surgical, Bausch + Lomb.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Rolls Out enVista Envy Premium Intraocular Lens Across Europe
- Bausch + Lomb announces European availability of enVista Envy lenses
- Bausch + Lomb to Unveil Broad New Ophthalmic Data at ASCRS Meeting
- Bausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI
- Bausch + Lomb Sets Date for First-Quarter 2026 Results and Investor Call